Match!
Anton Buzdin
Russian Academy of Sciences
GeneGene expressionGeneticsMedicineBiology
132Publications
28H-index
2,184Citations
What is this?
Publications 129
Newest
#1Maxim SorokinH-Index: 11
#2Kirill IgnatevH-Index: 1
view all 13 authors...
Increased expression or amplification of HER2 receptor tyrosine kinase gene ERBB2 is well-known and widely used as a prognostic biomarker of breast cancer (BC) response to the targeted treatment with trastuzumab and its analogs. Considering that part of the BC patients overexpressing HER2 does not respond to trastuzumab, clinical trial NCT03521245 was initiated to identify additional gene expression and molecular pathway activation response biomarkers to trastuzumab treatment in HER2-positive BC...
Source
#1Maxim Sorokin (RAS: Russian Academy of Sciences)H-Index: 1
#2I. V. KholodenkoH-Index: 8
Last. Sergey M. Deyev (RAS: Russian Academy of Sciences)H-Index: 22
view all 12 authors...
The tumor-associated ganglioside GD2 represents an attractive target for cancer immunotherapy. GD2-positive tumors are more responsive to such targeted therapy, and new methods are needed for the screening of GD2 molecular tumor phenotypes. In this work, we built a gene expression-based binary classifier predicting the GD2-positive tumor phenotypes. To this end, we compared RNA sequencing data from human tumor biopsy material from experimental samples and public databases as well as from GD2-pos...
Source
#1Elena PoddubskayaH-Index: 10
#2Maxim SorokinH-Index: 11
Last. Victor TkachevH-Index: 7
view all 14 authors...
e13676Background: Analysis of mutation profiles in cancer patients does not provide clinical benefits in 80-90% of cases in the US (Marquart et al., 2018). Gene expression analysis potentially comp...
Source
#1Maxim Sorokin (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 11
#2Kirill IgnatevH-Index: 1
view all 11 authors...
RNA sequencing is considered the gold standard for high-throughput profiling of gene expression at the transcriptional level. Its increasing importance in cancer research and molecular diagnostics is reflected in the growing number of its mentions in scientific literature and clinical trial reports. However, the use of different reagents and protocols for RNA sequencing often produces incompatible results. Recently, we published the Oncobox Atlas of RNA sequencing profiles for normal human tissu...
Source
#1Pieter Borger (UZH: University of Zurich)H-Index: 4
#1Pieter BorgerH-Index: 7
Last. Pierre-Alien Clavien (UZH: University of Zurich)
view all 7 authors...
Despite numerous studies addressing normal liver regeneration, we still lack comprehensive understanding of the biological processes underlying failed liver regeneration. Therefore, we analyzed the activity of 271 intracellular signaling pathways (ISPs) by genome wide profiling of differentially expressed RNAs in murine liver tissue biopsies after normal hepatectomy (nHx; 68% of liver removed) and extended hepatectomy (eHx; 86% of liver removed). Comprehensive, genome-wide transcriptome profilin...
Source
#1Darius Kalasauskas (University of Mainz)H-Index: 3
#2Maxim SorokinH-Index: 11
Last. Sven Reiner Kantelhardt (University of Mainz)
view all 13 authors...
Hypofractionated radiotherapy is the mainstay of the current treatment for glioblastoma. However, the efficacy of radiotherapy is hindered by the high degree of radioresistance associated with glioma stem cells comprising a heterogeneous compartment of cell lineages differing in their phenotypic characteristics, molecular signatures, and biological responses to external signals. Reconstruction of radiation responses in glioma stem cells is necessary for understanding the biological and molecular...
Source
#1Marianna A. Zolotovskaia (MIPT: Moscow Institute of Physics and Technology)H-Index: 1
Last. A. D. KaprinH-Index: 14
view all 15 authors...
Inter-patient molecular heterogeneity is the major declared driver of an expanding variety of anticancer drugs and personalizing their prescriptions. Here, we compared interpatient molecular heterogeneities of tumors and repertoires of drugs or their molecular targets currently in use in clinical oncology. We estimated molecular heterogeneity using genomic (whole exome sequencing) and transcriptomic (RNA sequencing) data for 4890 tumors taken from The Cancer Genome Atlas database. For thirteen m...
2 CitationsSource
#1Ella L. KimH-Index: 6
#1Ella L. Kim (University of Mainz)H-Index: 4
Last. Nurshat Gaifullin (MSU: Moscow State University)H-Index: 10
view all 15 authors...
Background: Inevitable recurrence after radiochemotherapy is the major problem in the treatment of glioblastoma, the most prevalent type of adult brain malignancy. Glioblastomas are notorious for a high degree of intratumor heterogeneity manifest through a diversity of cell types and molecular patterns. The current paradigm of understanding glioblastoma recurrence is that cytotoxic therapy fails to target effectively glioma stem cells. Recent advances indicate that therapy-driven molecular evolu...
4 CitationsSource
#1Giulia Negro (European Organisation for Research and Treatment of Cancer)H-Index: 1
#2Bertram Aschenbrenner (European Organisation for Research and Treatment of Cancer)H-Index: 1
Last. Maurizio Callari (University of Cambridge)H-Index: 21
view all 16 authors...
Background Metastatic progression of breast cancer is still a challenge in clinical oncology. Therefore, an elucidation how carcinoma cells belonging to different breast cancer subtypes realize their metastatic capacities is needed. The aim of this study was to elucidate a similarity of activated molecular pathways underlying an enhancement of invasiveness of carcinoma cells belonging to different breast carcinoma subtypes. Materials and methods In order to reach this aim, parental and invasive ...
1 CitationsSource
#1Anton Buzdin (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 2
#1Anton Buzdin (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 28
Last. Alexey Moiseev (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 2
view all 14 authors...
Abstract Molecular diagnostics is becoming one of the major drivers of personalized oncology. With hundreds of different approved anticancer drugs and regimens of their administration, selecting the proper treatment for a patient is at least nontrivial task. This is especially sound for the cases of recurrent and metastatic cancers where the standard lines of therapy failed. Recent trials demonstrated that mutation assays have a strong limitation in personalized selection of therapeutics, conseq...
10 CitationsSource
12345678910